Literature DB >> 15868139

The cyclopentenone prostaglandin 15-deoxydelta(12,14)-prostaglandin J2 attenuates the development of zymosan-induced shock.

Stefania Marzocco1, Rosanna Di Paola, Emanuela Mazzon, Tiziana Genovese, Domenico Britti, Aldo Pinto, Giuseppina Autore, Salvatore Cuzzocrea.   

Abstract

OBJECTIVE: Multiple-organ failure (MOF) is defined as the progressive deterioration in function which occurs in several organs or systems in patients with septic shock, multiple trauma, severe burns, or pancreatitis. This study investigated the effect of 15-deoxy-delta(12,14)-PGJ2 (15d-PGJ2), a PPAR-gamma ligand, in a model of zymosan-induced nonseptic shock in mice.
MATERIALS AND METHODS: Mice were randomly assigned to one of four groups (n=10 each) and treated i.p. as follows: group 1, zymosan (500 mg/kg suspended in saline solution) and vehicle (10% DMSO); group 2, zymosan (500 mg/kg suspended in saline solution) plus 15d-PGJ2 (30 microg/kg, suspended in 10% DMSO) 1 h before and 6 h after zymosan administration; group 3, 15d-PGJ2 (30 microg/kg, suspended in 10% DMSO; group 4, vehicle for PGJ2 (10% DMSO) always 1 h before and 6 h after saline administration. After 18 h mice were killed and tissues and biological fluids used for biochemical, immunohistochemical, and histological analysis. MEASUREMENTS AND
RESULTS: 15d-PGJ2 inhibited the inflammatory response and significantly reduced peritoneal mononuclear cell infiltration and histological injury in mice. A significant protection was demonstrated in kidney, liver, and pancreas injury by the reduction in amylase, lipase, creatinine, AST, ALT, bilirubin, and alkaline phosphatase levels. 15d-PGJ2 also reduced the appearance of nitrotyrosine in the inflamed intestinal tissues. Histological examination revealed a significant reduction in zymosan-induced intestinal damage in 15d-PGJ2 treated mice.
CONCLUSIONS: Our findings demonstrate that 15d-PGJ2 exerts potent anti-inflammatory effects on zymosan-induced shock.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868139     DOI: 10.1007/s00134-005-2596-2

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  39 in total

1.  Inducible nitric oxide synthase knockout mice exhibit resistance to the multiple organ failure induced by zymosan.

Authors:  S Cuzzocrea; E Mazzon; L Dugo; A Barbera; T Centorrino; A Ciccolo; M T Fonti; A P Caputi
Journal:  Shock       Date:  2001-07       Impact factor: 3.454

2.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

Authors:  V Pasceri; H D Wu; J T Willerson; E T Yeh
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

3.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

Authors:  A C Li; K K Brown; M J Silvestre; T M Willson; W Palinski; C K Glass
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

4.  The cyclopentone prostaglandin 15-deoxy-Delta(12,14) prostaglandin J2 represses nitric oxide, TNF-alpha, and IL-12 production by microglial cells.

Authors:  P D Drew; J A Chavis
Journal:  J Neuroimmunol       Date:  2001-04-02       Impact factor: 3.478

5.  The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis.

Authors:  Christian Brun-Buisson; Françoise Roudot-Thoraval; Emmanuelle Girou; Catherine Grenier-Sennelier; Isabelle Durand-Zaleski
Journal:  Intensive Care Med       Date:  2003-07-10       Impact factor: 17.440

6.  Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase.

Authors:  Thomas J H Volman; R Jan A Goris; Michel van der Jagt; Fons A J van de Loo; Thijs Hendriks
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

7.  Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin.

Authors:  Marika Collin; Nimesh S A Patel; Laura Dugo; Christoph Thiemermann
Journal:  Crit Care Med       Date:  2004-03       Impact factor: 7.598

8.  Protective effects of M40401, a selective superoxide dismutase mimetic, on zymosan-induced nonseptic shock.

Authors:  Salvatore Cuzzocrea; Emanuela Mazzon; Rosanna Di Paola; Tiziana Genovese; Ivana Serraino; Laura Dugo; Elisabetta Cuzzocrea; Francesco Fulia; Achille P Caputi; Daniela Salvemini
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

9.  Comparison between lung and liver lipid peroxidation and mortality after zymosan peritonitis in the rat.

Authors:  R Demling; U Nayak; K Ikegami; C LaLonde
Journal:  Shock       Date:  1994-09       Impact factor: 3.454

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  3 in total

1.  Modeling MODS: what can be learned from animal models of the multiple-organ dysfunction syndrome?

Authors:  John C Marshall
Journal:  Intensive Care Med       Date:  2005-03-22       Impact factor: 17.440

Review 2.  Year in review in intensive care medicine, 2005. III. Nutrition, pediatric and neonatal critical care, and experimental.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-18       Impact factor: 17.440

3.  Effects of 15-deoxy-Delta12,14-prostaglandin-J2 during hyperdynamic porcine endotoxemia.

Authors:  Balázs Hauser; Jochen Kick; Zsolt Iványi; Pierre Asfar; Ulrich Ehrmann; Claus-Martin Muth; Maura Albicini; Ulrich Wachter; Josef Vogt; Michael Bauer; Uwe Bernd Brückner; Peter Radermacher; Hendrik Bracht
Journal:  Intensive Care Med       Date:  2006-03-14       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.